People: Onyx Pharmaceuticals Inc (ONXX.OQ)

Summary

Name	Age	Since	Current Position
N. Anthony Coles	52	2012	Chairman of the Board, President, Chief Executive Officer
Matthew Fust	48	2009	Chief Financial Officer, Executive Vice President
Suzanne Shema	55	2012	Executive Vice President, General Counsel, Corporate Secretary
Pablo Cagnoni	48	2013	Executive Vice President - Global Research & Development and Technical Operations
Juergen Lasowski	55	2011	Executive Vice President - Corporate Development and Strategy
Helen Torley	50	2011	Executive Vice President, Chief Commercial Officer
Kaye Foster-Cheek	53	2010	Senior Vice President - Global Human Resources
Julianna Wood	57	2011	Vice President - Public Affairs
Paul Goddard	63	2008	Lead Independent Director
Antonio Grillo-Lopez	73	2002	Independent Director
Magnus Lundberg	57	2000	Independent Director
Corinne Nevinny	53	2005	Independent Director
William Ringo	67	2011	Independent Director
Wendell Wierenga	65	1996	Independent Director
Thomas Wiggans		2005	Independent Director
Amy Figueroa			IR Contact Officer

» Insider Trading

Biographies

Name	Description
N. Anthony Coles	Dr. N. Anthony Coles, Jr., M.D., is Chairman of the Board, President, Chief Executive Officer of Onyx Pharmaceuticals, Inc. He has served as the Company's President, Chief Executive Officer and Director since 2008. In December 2012, Dr. Coles was elected Chairman of the Board, while continuing to serve as the Company's President and Chief Executive Officer. From May 2006 to March 2008, Dr. Coles served as President, Chief Executive Officer, and Director of NPS Pharmaceuticals, Inc., a public biotechnology company. Prior to 2007, Dr. Coles served in numerous leadership positions in the biopharmaceutical and pharmaceutical industries. Dr. Coles earned his M.D. from Duke University, his master's degree in public health from Harvard College and his undergraduate degree from Johns Hopkins University. Dr. Coles currently serves as a trustee and member of the Executive Committee for the Johns Hopkins University Board of Trustees, as well as a member of the board of trustees for Johns Hopkins Medicine. During 2012, Dr. Coles also served on the boards of Laboratory Corporation of America Holdings, a public medical testing company, and Campus Crest Communities, Inc., a public student housing company. Dr. Coles has stepped down from both of these public company boards in order to focus time and energy on the expansion of Onyx, as it continues its growth in the United States and globally. He is currently a member of the board of the Biotechnology Industry Organization, the world's biotechnology trade association. In his leadership positions at several public companies, Dr. Coles has managed pharmaceutical product pipelines, overseen launches of numerous pharmaceutical products, and built commercial organizations. In addition, he has been responsible for strategic planning and corporate development at several public biotechnology and biopharmaceutical companies.
Matthew Fust	Mr. Matthew K. Fust is Chief Financial Officer, Executive Vice President of Onyx Pharmaceuticals, Inc., since January 5, 2009. From May 2003 to December 2008, Mr. Fust served as Chief Financial Officer at Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company. From 2002 to 2003, Mr. Fust served as Chief Financial Officer at Perlegen Sciences, a biopharmaceutical company. Previously, he was Senior Vice President and Chief Financial Officer at ALZA Corporation, a public pharmaceutical company, where he was an executive from 1996 until 2002. Mr. Fust serves on the Board of Directors of Sunesis Pharmaceuticals, a public biopharmaceutical company. Mr. Fust received a B.A. from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business.
Suzanne Shema	Ms. Suzanne M. Shema, J.D., is Executive Vice President, General Counsel, Corporate Secretary of Onyx Pharmaceuticals, Inc. She joined the company as Senior Vice President and General Counsel in August 2009. In January 2012, Ms. Shema was appointed Executive Vice President and Corporate Secretary. From 2006 to 2009, Ms. Shema served as General Counsel and Corporate Compliance Officer at ZymoGenetics, Inc., a biopharmaceutical company. Ms. Shema received a B.S. in Chemistry from the University of Texas, an M.S. in Chemistry from the University of Washington and a J.D. from the University of Washington School of Law.
Pablo Cagnoni	Dr. Pablo J. Cagnoni, M.D., has been appointed as Executive Vice President - Global Research & Development and Technical Operations of Onyx Pharmaceuticals Inc., effective March 2013. Before joining the company, Dr. Cagnoni was Senior Vice President and Global Head of Clinical Development of Novartis Oncology. Prior to joining Novartis in 2009, Dr. Cagnoni served as Senior Vice President and Chief Medical Officer at Allos Therapeutics, Inc. Before joining Novartis, Dr. Cagnoni served as Chief Medical Officer and Vice President of Clinical Research and Medical Affairs at OSI Pharmaceuticals. Before joining OSI Pharmaceuticals, he served as Vice President and Head of Clinical Development at Allos Therapeutics. Previous to his industry experience, Dr. Cagnoni was Assistant Professor of Medicine and Assistant Director Pharmacology Laboratory, University of Colorado Bone Marrow Transplant Program. Dr. Cagnoni earned his medical degree from University Buenos Aires School of Medicine and he completed his fellowship in Hematology and Oncology, in the Division of Hematology, Department of Medicine at Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center.
Juergen Lasowski	Dr. Juergen Lasowski, Ph.D., is Executive Vice President - Corporate Development and Strategy of Onyx Pharmaceuticals, Inc. He joined the company as Senior Vice President, Corporate Development in May 2008. In February 2011, Dr. Lasowski was appointed Executive Vice President, Corporate Development and Strategy. From April 2006 to October 2007, Dr. Lasowski was the Senior Vice President of Corporate Development at NPS Pharmaceuticals. Dr. Lasowski earned a Ph.D. in organic chemistry from the University of Mainz, Germany and an M.B.A. from INSEAD in France.
Helen Torley	Dr. Helen I. Torley, M.B. Ch. B., M.R.C.P., is Executive Vice President, Chief Commercial Officer of Onyx Pharmaceuticals, Inc., since August 31, 2011. Dr. Torley oversees all of the commercial activities for Nexavar and the launch of Kyprolis and oversees the development of the commercial capabilities in Europe. From 2002 to 2011, Dr. Torley held various positions at Amgen where she most recently served as vice president and general manager of the Bone Health Unit, after leading the company's Nephrology Business Unit for five years. Dr. Torley received her M.B. Ch.B (the U.K. equivalent of an M.D.) from the University of Glasgow and is a Member of the Royal College of Physicians.
Kaye Foster-Cheek	Ms. Kaye I. Foster-Cheek is Senior Vice President, Global Human Resources of Onyx Pharmaceuticals Inc., since September 2010. From May 2003 to March 2010, Ms. Foster-Cheek was Vice President of Human Resources and Executive Committee Member at Johnson & Johnson where she was responsible for the human resources and talent management functions. Ms. Foster-Cheek earned her undergraduate degree at Baruch College of the City University of New York and received an M.B.A. from Columbia University, Graduate School of Business.
Julianna Wood	Ms. Julianna R. Wood is Vice President - Public Affairs of Onyx Pharmaceuticals, Inc. She joined as Vice President, Corporate Communications and Investor Relations in May 2003. In January 2011, Ms. Wood was appointed Vice President, Public Affairs. From December 2001 to May 2003, Ms. Wood was Senior Director of Investor Relations and Corporate Communications at Caliper Technologies Corporation. Previously, she served in a similar capacity at Sangamo BioSciences, Inc. and Chiron Corporation. Ms. Wood holds a B.A. from Stanford University and has an M.B.A. from Duke University.
Paul Goddard	Dr. Paul Goddard, Ph.D., is Lead Independent Director of Onyx Pharmaceuticals Inc. Dr. Goddard has served as a Director since February 1997. Dr. Goddard served as Chief Executive Officer of ARYx Therapeutics, a public biotechnology company, from April 2005 to November 2011 and has served as its Chairman of the Board of Directors since August 2003. Dr. Goddard served on the Board of Directors of Adolor Corporation, a biotechnology company, from October 2000 until December 2011. Prior to 2007, Dr. Goddard's business experience included serving as Chief Executive Officer of Elan Pharmaceuticals, Inc., and Chief Executive Officer and Chairman of the Board of Neurex Corporation. Dr. Goddard also serves on the Boards of Directors of Pathway Corporation and Hemaquest Inc. Until June 2012, Dr. Goddard also served on the board of A.P. Pharma, Inc., a public pharmaceutical company, where he was also Chairman of the Board. He completed his Ph.D. in the area of Etiology and Pathophysiology of colon cancer at St. Mary's Hospital, University of London. Dr. Goddard has knowledge of, and experience in, the pharmaceutical industry.
Antonio Grillo-Lopez	Dr. Antonio J. Grillo-Lopez, M.D., is an Independent Director of Onyx Pharmaceuticals, Inc., since September 26, 2002. Since 2010, Dr. Grillo-López has served as a consultant to Optimer Corp., HUYA Bioscience and Biogen Idec. Between 2007 and 2009, Dr. Grillo-López served as a consultant to various other biotech companies, including Hexal Pharma, Memgen Pharma and Tracon Pharma. From 2001 to 2008, Dr. Grillo-López served on the Board of Directors of Favrille, Inc., a public biopharmaceutical company. Prior to 2007, Dr. Grillo-López served in a Chief Medical Officer capacity with two companies in the pharmaceutical industry, served as a consultant to the U.S. National Cancer Institute and served on the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration. Dr. Grillo-López also serves on the Board of Trustees of the Hope Funds for Cancer Research. Dr. Grillo-López is a Hematologist and Oncologist and holds a B.S. and an M.D. from the University of Puerto Rico.
Magnus Lundberg	Mr. Magnus Lundberg is an Independent Director of Onyx Pharmaceuticals, Inc., since June 2000. Since September 2011, Mr. Lundberg has served as non-executive Chairman and Director of Atos Medical AB, a global medical device company. From June 2012, Mr. Lundberg has served as non-executive Chairman and Director of Airsonett AB, a private medical technology company, and from September 2012, as a non-executive Director of Convatec Inc., a medical device company, and since February 2013, Mr. Lundberg has also served as Chairman of Convatec. From 2004 until its acquisition in 2011, Mr. Lundberg served as President and Chief Executive Officer of Phadia AB, a medical diagnostic company. Prior to 2007, Mr. Lundberg served in leadership positions at several companies in the biopharmaceutical, pharmaceutical and biotechnology industries. Mr. Lundberg holds an M.Sc. in Biology and Biochemistry from Abo Akademi in Turku, Finland.
Corinne Nevinny	Ms. Corinne H. Nevinny is an Independent Director of Onyx Pharmaceuticals, Inc., since October 6, 2005. Ms. Nevinny is currently General Partner of LMNVC LLC, a privately held venture firm she founded in October 2010. Since December 2010 she has also served as acting President and CFO for Fight 2 B Fit, Inc., a privately held fitness company. From September 2009 to August 2010, she served as General Manager, Cardiac Surgery and Vascular, at Edwards Lifesciences Corporation, a cardiovascular technology company. Prior to assuming that position, she was President of Global Operations from December 2005 until September 2009. Prior to 2005, Ms. Nevinny served as an officer and chief financial officer to Edwards Lifesciences Corporation and chief financial officer and treasurer of Tularik, Inc., and as an Executive Director at Warburg Dillon Read LLC. Ms. Nevinny also serves on the Board of Directors of Neurocrine Biosciences, Inc., a public biopharmaceutical company, as well as three private companies. Since March 2013, she has also served as a Director of Avanir Pharmaceuticals, Inc., a public biopharmaceutical company. Ms. Nevinny received her undergraduate degree from Stanford University and her M.B.A. from Harvard Business School.
William Ringo	Mr. William R. Ringo, Jr., is an Independent Director of Onyx Pharmaceuticals Inc., since February 3, 2011. Mr. Ringo currently serves as Executive Partner at Sofinnova Ventures and Senior Advisor to Barclays Capital. From 2008 until his retirement in 2010, Mr. Ringo served as Senior Vice President of Strategy and Business Development for Pfizer. Prior to 2007, Mr. Ringo served in a number of leadership positions in the pharmaceutical, biotechnology and financial industries. Mr. Ringo holds a bachelor's degree and MBA from the University of Dayton. He is the current Chairman of Sangamo BioSciences, a public biopharmaceutical company, and serves as a director for Alvine Pharmaceuticals, Inc. and BioCrossroads.
Wendell Wierenga	Dr. Wendell Wierenga, Ph.D., is an Independent Director of Onyx Pharmaceuticals, Inc., since December 1996. Since June 2011, Dr. Wierenga has served as Executive Vice President of Research and Development of Santarus, Inc., a specialty pharmaceutical company. From January 2007 to June 2011, Dr. Wierenga served as Executive Vice President of Research and Development of Ambit Biosciences Corporation, a biopharmaceutical company. Prior to 2007, Dr. Wierenga served in leadership capacities at several biotechnology companies and in the pharmaceutical and investment fund industry. Dr. Wierenga also serves on the Board of Directors of Cytokinetics, Inc., a public biotechnology company, and XenoPort, Inc., a public pharmaceutical company. Dr. Wierenga holds a B.A. from Hope College and a Ph.D. in chemistry from Stanford University.
Thomas Wiggans	Mr. Thomas G. Wiggans is an Independent Director of Onyx Pharmaceuticals, Inc., since March 10, 2005. Since August 2010, Mr. Wiggans has served as Chief Executive Officer and Director of Dermira, Inc., a private biotechnology company he co-founded in 2010. Mr. Wiggans served as Chairman of the Board of Directors of Peplin, Inc., a public biotechnology company, from 2007 until its acquisition by LEO Pharma in 2009. From 2008 to 2009, Mr. Wiggans also served at the Chief Executive Officer of Peplin, Inc. During 2007, Mr. Wiggans served on the boards of various other private companies. Prior to 2007, Mr. Wiggans served in leadership capacities in several companies in the biotechnology and pharmaceutical industry. Until 2012, Mr. Wiggans served as a Director of Sangamo Biosciences, a public biopharmaceutical company and Somaxon Pharmaceuticals, Inc., a public pharmaceutical company; however, Mr. Wiggans did not stand for re-election as Director in 2012 for either company. Mr. Wiggans continues to serve as a Director of Lithera, Inc., a private clinical stage pharmaceutical company. He also serves on the Board of Trustees of the University of Kansas Endowment Association. In addition, he is Chairman of the Biotechnology Institute, a non-profit educational organization. Mr. Wiggans holds a B.S. in Pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University. Mr. Wiggans has knowledge of the biotechnology industry. He has served in leadership positions with biotechnology companies during key growth periods and has developed and launched multiple pharmaceutical products.
Amy Figueroa

Basic Compensation

Name	Fiscal Year Total
N. Anthony Coles	7,362,940
Matthew Fust	2,513,370
Suzanne Shema	2,724,080
Pablo Cagnoni	--
Juergen Lasowski	2,426,130
Helen Torley	3,346,430
Kaye Foster-Cheek	1,803,610
Julianna Wood	--
Paul Goddard	--
Antonio Grillo-Lopez	--
Magnus Lundberg	--
Corinne Nevinny	--
William Ringo	--
Wendell Wierenga	--
Thomas Wiggans	--
Amy Figueroa	--

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
N. Anthony Coles	375,599	18,204,900
Matthew Fust	23,458	558,834
Suzanne Shema	99,485	2,828,910
Pablo Cagnoni	0	0
Juergen Lasowski	14,000	541,674
Helen Torley	0	0
Kaye Foster-Cheek	0	0
Julianna Wood	0	0
Paul Goddard	0	0
Antonio Grillo-Lopez	0	0
Magnus Lundberg	0	0
Corinne Nevinny	0	0
William Ringo	0	0
Wendell Wierenga	0	0
Thomas Wiggans	0	0
Amy Figueroa	0	0

Insider Trading

Name	Shares Traded	Price
NEVINNY CORINNE HELENE	1,000	$88.25
WOOD JULIANNA R	719	$37.68
WOOD JULIANNA R	219	$30.28
WOOD JULIANNA R	547	$35.18
WOOD JULIANNA R	547	$30.28
WOOD JULIANNA R	274	$28.55
WOOD JULIANNA R	2,306	$92.30
SHEMA SUZANNE M	796	$37.68
SHEMA SUZANNE M	1,214	$32.07
SHEMA SUZANNE M	1,100	$92.06
SHEMA SUZANNE M	2,952	$90.91
SHEMA SUZANNE M	802	$35.18
SHEMA SUZANNE M	584	$37.68
SHEMA SUZANNE M	656	$30.28
COLES NEAVELLE ANTHONY	6,562	$35.18
COLES NEAVELLE ANTHONY	6,562	$90.00
WIGGANS THOMAS G	850	$0.00
LASOWSKI JUERGEN	2,988	$96.38
LASOWSKI JUERGEN	1,194	$97.13
TORLEY HELEN	1,250	$37.68
TORLEY HELEN	2,500	$98.28
FUST MATTHEW K	6,000	$98.70
TORLEY HELEN	1,750	$97.32
TORLEY HELEN	3,000	$98.78
TORLEY HELEN	7,000	$33.70

» Full list on Insider Trading

People: Onyx Pharmaceuticals Inc (ONXX.OQ)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: